Corporate

CLINUVEL
Posted by CLINUVEL
May 26, 2022

H.C. Wainwright Global Investment Conference 2022

CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the H.C. Wainwright...

Read More
CLINUVEL
Posted by CLINUVEL
May 13, 2022

Strategic Update IV

CLINUVEL today announced its fourth Strategic Update, focused on the Group’s view...

Read More
CLINUVEL
Posted by CLINUVEL
April 8, 2022

CLINUVEL Kommuniqué II

At CLINUVEL our path has been set and we continue to grow...

Read More
CLINUVEL
Posted by CLINUVEL
April 6, 2022

Chair's Letter

In my first letter to you for 2022 I provide updates on...

Read More
CLINUVEL
Posted by CLINUVEL
March 31, 2022

CLINUVEL Communiqué II

At CLINUVEL our path has been set and we continue to grow...

Read More
CLINUVEL
Posted by CLINUVEL
March 17, 2022

ACTH Manufacturing Update

CLINUVEL is progressing scaled manufacturing of adrenocorticotropic hormone (ACTH) under current Good...

Read More
CLINUVEL.
Posted by CLINUVEL.
January 28, 2022

CLINUVEL Kommuniqué 1

Happy New Year to all our stakeholders for 2022, a year in...

Read More
CLINUVEL.
Posted by CLINUVEL.
January 27, 2022

CLINUVEL Communiqué 1

Happy New Year to all our stakeholders for 2022, a year in...

Read More
CLINUVEL
Posted by CLINUVEL
January 10, 2022

CLINUVEL’S GROWTH AND EXPANSION - H.C. Wainwright Bioconnect Conference 2022

CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the H.C. Wainwright...

Read More
CLINUVEL
Posted by CLINUVEL
December 23, 2021

Progress of CLINUVEL’s DNA Repair Program

CLINUVEL PHARMACEUTICALS LTD today announced that two xeroderma pigmentosum (XP) patients have...

Read More
CLINUVEL
Posted by CLINUVEL
December 21, 2021

Chair's Letter to Shareholders

On behalf of the Board, thank you to those shareholders who chose...

Read More
CLINUVEL
Posted by CLINUVEL
December 21, 2021

CLINUVEL Kommuniqué VI

Der letzte Monat war eine tragische Lektion in Bezug auf die Herausforderungen...

Read More
CLINUVEL.
Posted by CLINUVEL.
December 20, 2021

SCENESSE® as Vitiligo Monotherapy

CLINUVEL’s drug SCENESSE® (afamelanotide 16mg) will be evaluated as a monotherapy in...

Read More
CLINUVEL
Posted by CLINUVEL
December 20, 2021

CLINUVEL Communiqué VI

The last month has been a tragic lesson in the challenges posed...

Read More
CLINUVEL
Posted by CLINUVEL
November 24, 2021

CLINUVEL Kommuniqué V

CLINUVELs fünftes Nachrichtenkommuniqué für 2021. Bespricht EPP, klinisches Programm, IR-Update und mehr.

Read More